Peeling paint. Cracked buckets. Employees dragging unsealed bags of medical waste. Procedures ignored. Inadequately trained staff. All of these were problems noted by U.S. Food and Drug Administration inspectors at the Emergent BioSolutions factory in Baltimore – a facility that is intended to produce materials for the Johnson & Johnson COVID-19 vaccine.Read More
Operation Warp Speed, the Trump administration's push to make a COVID-19 vaccine available in record time, added $628 million to a federal contract with Emergent BioSolutions, a Maryland-based contract manufacturer, "to advance manufacturing capabilities and capacity for a potential COVID-19 vaccine as well as therapeutics," the Department of Health and Human Services Read More